Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-F1
2023-510098-33-01Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of surovatamig in follicular lymphoma (FL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety evaluation of surovatamig in combination with rituximab, Recommended Phase III dose and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
surovatamig
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-510098-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510098-33-01.